Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures

Han, Shan; Li, Ximing; Ali, Lamees Abdullah Mohammed; Fu, Naikuan; Jin, Di; Cong, Hongliang

doi:10.1016/j.ijcard.2013.07.252

Cited by 8 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to that meta-analysis, this study included 11 additional trials (2256 participants) performed in China. However, 2 trials [26,27] included in the study by Xin W et al were excluded from our study; 1 study lacked detailed information on the volume of contrast medium volume, and the other had only 1 patient with CI-AKI. The contrast medium volume is an independent predictor correlated to CI-AKI.…”

Section: Discussionmentioning

confidence: 99%

Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials

Cui

Xie²,

Wang³

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Preventing contrast-induced acute kidney injury (CI-AKI) is critical because of its association with poor clinical outcomes, including extended hospital stays and increased mortality. The effects of probucol on preventing CI-AKI have been controversial. Therefore, this systematic review and meta-analysis evaluated the influence of probucol combined with hydration on the CI-AKI risk in patients with coronary heart disease undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). Methods: We retrieved data from the following databases from their inception to May 29, 2022: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database (Sinomed), Wanfang Database, and Chinese Scientific Journal Database. The methodological quality of the trials was assessed following the Cochrane Handbook guidelines, and Review Manager 5.3 and Stata 14.0 software were used for the data analysis. Results: We included 14 trials comprising 3306 patients in the analysis. All included trials reported the CI-AKI incidence rate (the primary outcome). Probucol with hydration significantly reduced the CI-AKI incidence compared to hydration alone (odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.25–0.44, P < .001). Subgroup analyses were performed based on the contrast medium type (iso-osmolality vs low-osmolality contrast medium [LOCM]) and volume (less than or more than 200 mL); the effects of probucol with hydration versus hydration-only on CI-AKI were comparable within each subgroup. Additionally, the serum creatinine (Scr) concentration 24 hours, 48 hours, and 72 hours and the estimated glomerular filtration rate (eGFR) 72 hours after contrast exposure were better in the probucol with hydration group than the hydration-only group. Finally, major clinical adverse events and adverse drug reactions were comparable between the probucol with hydration and hydration-only groups. Conclusion: Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI. However, more high-quality, large-sample, multicenter randomized trials are needed to confirm this conclusion.

show abstract

Section: Discussionmentioning

confidence: 99%

Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials

Cui

Xie²,

Wang³

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Combination of atorvastatin with probucol has been also suggested to be superior to single-agent atorvastatin 23 in the prevention of contrast-induced nephropathy by a clinical study. However, there are fewer research on the combination of atorvastatin, probucol and alprostadil for CIAKI, [24][25] and the link between probucol, alprostadil and ERS-induced apoptotic pathway has not been investigated. This study established a rat CIAKI model using meglumine diatrizoate, then compared the combination of atorvastatin with probucol or alprostadil with single application of atorvastatin by observing the expression of markers such as GRP78, CHOP/GADD153, Caspase-12 in apoptosis pathway induced by ERS at protein and nucleic acid levels.…”

Section: Introductionmentioning

confidence: 99%

Combination of different drugs can enhance prevention of CIAKI through inhibition of endoplasmic reticulum stress-induced apoptotic pathway

Wang,

Han,

Cong

2024

Preprint

View full text Add to dashboard Cite

Introduction: Contrast-induced acute kidney injury(CIAKI) is an important clinical complication that occurs after the application of contrast in percutaneous coronary intervention. The pathogenesis of CIAKI is complex. Studies have shown that the cell apoptosis induced by endoplasmic reticulum stress (ERS) play an important role in the renal tubular injury of CIAKI. It was suggested that atorvastatin, probucol and alprostadil can inhibit renal tubular cell apoptosis to prevent CIAKI. However, there is no specific research about the above effect of the drug combination. Therefore, this study intends to establish the rat CIAKI model by meglumine diatrizoate and add drug intervention, to compare the influence of combined drugs with the single atorvastatin for CIAKI by inhibiting ERS specific molecular chaperone. Method and Result: 50 Wistar rats were randomly divided into 5 groups: Group A (atorvastatin group, n=10); Group P (probucol + atorvastatin group, n=10); Group Q (alprostadil + atorvastatin group, n=10); Group NC (contrast group, n=10); Group N (control group, n=10). After treated with meglumine diatrizoate and different drugs, the kidneys were obtained for HE, TUNEL staining and real-time RT-PCR, western blot, immunohistochemitry to detect the expression of nucleic acid and protein levels of GRP78, GADD153/CHOP, Caspase-12 in the ERS pathways. Group NC has the significantly highest creatinine rise rate, expression level of protein and nucleic acid in the five groups, with the most serious cell injury and apoptosis in HE and TUNEL staining. Compared with the single atorvastatin group, creatinine rise rate and expression of protein in the combined medication groups were decreased to some extent, whose histological morphology was also improved. This was especially evident in the group Q. Conclusion: The renal cell apoptosis induced by ERS pathway may play an important role in pathogenesis of CIAKI induced by meglumine diatrizoate. Atorvastatin, probucol and alprostadil can prevent the occurrence of CIAKI, may through the inhibition of cell apoptosis induced by ERS pathway. The protective effect for CIAKI of probucol or alprostadil combined with atorvastatin may be stronger than the single atorvastatin through ERS pathway, with the more effect of the combination of alprostadil and atorvastatin.

show abstract

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Lewicki

Schneider

2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures

Cited by 8 publications

References 7 publications

Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials

Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials

Combination of different drugs can enhance prevention of CIAKI through inhibition of endoplasmic reticulum stress-induced apoptotic pathway

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Contact Info

Product

Resources

About